Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

GENMAB

GMAB.CODK0010272202NASDAQ CopenhagenDKDKK
Stock price
GENMAB
Loading chart...

Coverage

Latest articles

Genmab's experimental cancer drug shows encouraging results in endometrial cancer trial
8 Jun 2025, 20:28GMAB.CONASDAQ Copenhagen

Filings

Recent filings

FilingDate
Genmab, Announces HuMax-ZP3 Cancer Program13 Dec 2006
Genmab, Grant of Warrants in Genmab A/S13 Dec 2006
Genmab, Initiates HuMax-CD20 Front Line CLL Study11 Dec 2006
Genmab, Announces Additional Positive Results In HuMax-CD20 CLL Phase I/II Study11 Dec 2006
Genmab, Announces Early Results of Ongoing HuMax-CD4 Trials10 Dec 2006
Genmab, articles of association on December 4, 20066 Dec 2006
InvestorService: Genmab, Genmab's Partner Roche Identifies Disease Areas Addressed in Collaboration5 Dec 2006
Genmab, announces Positive Interim Data for the HuMax-CD20 Phase II RA Study
Search

Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.

  • Previous
  • 1
  • 2
  • 3
  • Next
5 Dec 2006
Genmab, Capital increase in Genmab as a result of employee warrant exercise4 Dec 2006
InvestorService: Genmab, to Present at Piper Jaffray 18th Annual Health Care Conference21 Nov 2006
Genmab, Licenses MIF Receptor Target from Cytokine PharmaSciences20 Nov 2006
Genmab, Roche Presents Positive Preclinical Data on Genmab Antibody8 Nov 2006
  • Previous
  • 1
  • More pages
  • 123
  • 124
  • 125
  • More pages
  • 156
  • Next
Company
GENMAB
GMAB.CONASDAQ Copenhagen
Website: Unavailable
Coverage
13
Filings
1,863